Guideline for the Management of Nephrotic Syndrome



Similar documents
Diabetic nephropathy is detected clinically by the presence of persistent microalbuminuria or proteinuria.

FURTHER EXPERIENCE WITH SUBCUTANEOUS IMMUNOGLOBULIN THERAPY IN CHILDREN WITH PRIMARY IMMUNE DEFICIENCIES

Lothian Diabetes Handbook MANAGEMENT OF DIABETIC KETOACIDOSIS

Treating myeloma. Dr Rachel Hall Royal Bournemouth Hospital

HYPERTENSION ASSOCIATED WITH RENAL DISEASES

Diabetes and the Kidneys

Breast Pathway Group FEC 60 (Fluorouracil / Epirubicin / Cyclophosphamide) in Early Breast Cancer in Elderly / Frail

Cyclophosphamide/Rabbit Anti-Thymocyte Globulin for Allograft

Guideline for Microalbuminuria Screening

Chronic Kidney Disease (CKD) Algorithm. Chronic Kidney Disease (CKD) Algorithm Page 1

INTRAVENOUS FLUIDS. Acknowledgement. Background. Starship Children s Health Clinical Guideline

NICE Pathways bring together all NICE guidance, quality standards and other NICE information on a specific topic.

Renal Disease in Type 2 Diabetes Mellitus

Docetaxel + Carboplatin + Trastuzumab (TCH) Adjuvant Breast Cancer

ESIM 2014 WHEN CHRONIC BECOMES ACUTE

Laboratory Monitoring of Adult Hospital Patients Receiving Parenteral Nutrition

POAC CLINICAL GUIDELINE

Intraosseous Vascular Access and Lidocaine

Treatment Recommendations for CKD in Cats (2015)

Registered Charity No: Caring for those with a rare, complex and lifelong disease

Lung Pathway Group Pemetrexed and Cisplatin in Non-Small Cell Lung Cancer (NSCLC)

Diabetic Ketoacidosis

Breast Pathway Group AC (Doxorubicin / Cyclophosphamide) in Early Breast Cancer

A patient guide to membranous nephropathy

Southern Derbyshire Shared Care Pathology Guidelines. AKI guidelines for primary care

LEFLUNOMIDE (Adults)

Hyperosmolar Non-Ketotic Diabetic State (HONK)

Hydration Protocol for Cisplatin Chemotherapy

Nige g ri e an a N at a ional a Antimal a ari a a Tre re t a men e t g ide d l e ines

Shared Care Guideline for the use of Leflunomide for Rheumatoid Arthritis

PREMEDICATIONS: Agent(s) Dose Route Schedule

This regimen has low emetogenic potential refer to local protocol None required routinely. Baseline results valid for 7 days. Results valid for 72 hrs

BCCA Protocol Summary for Advanced Therapy for Relapsed Testicular Germ Cell Cancer Using PACLitaxel, Ifosfamide and CISplatin (TIP)

Identifying and treating long-term kidney problems (chronic kidney disease)

CLINICAL GUIDELINE FOR MANAGEMENT OF NEUTROPENIC SEPSIS IN CANCER PATIENTS 1. Aim/Purpose of this Guideline

Treatment of diseases affecting the kidney using steroids

Background Information Myeloma

SOP for Screening of Adult Chemotherapy Electronic Prescriptions

Diabetic Nephropathy

Most probable Diagnosis

LYMPHOMA IN DOGS. Diagnosis/Initial evaluation. Treatment and Prognosis

Interferon beta products: risk of thrombotic microangiopathy and nephrotic syndrome

DAYTON CHILDREN S HOSPITAL CLINICAL PRACTICE GUIDELINES

Initiate Atorvastatin 20mg daily

Diagnostics: Page 2 of 5

PRESCRIBING GUIDELINES FOR THE MANAGEMENT OF PATIENTS ANTICOAGULANT THERAPY

An overview of CLL care and treatment. Dr Dean Smith Haematology Consultant City Hospital Nottingham

Exceptional People. Exceptional Care. Antenatal Appointment Schedule for Normal Healthy Women with Singleton Pregnancies

Hypertension Guidelines

patient group direction

3. The near patient testing service is designed to be one in which:

Beaumont Hospital Department of Nephrology and Renal Nursing. Guideline for administering Ferinject

BCCA Protocol Summary for Palliative Treatment of Advanced Pancreatic Neuroendocrine Tumours using SUNItinib (SUTENT )

UCSF Kidney Transplant Symposium 2012

MANAGEMENT OF INFANTS BORN TO HIV POSITIVE MOTHERS

GUIDELINES FOR TUBERCULOSIS PREVENTIVE THERAPY AMONG HIV INFECTED INDIVIDUALS IN SOUTH AFRICA

Health Technology Appraisal- Continuous subcutaneous insulin infusion for the treatment of diabetes (review)

Primary Care Management of Male Lower Urinary Tract Symptoms. Matthew B.K. Shaw Consultant Urological Surgeon

Cardiovascular Risk in Diabetes

Children on Long Term Anticoagulation. Elizabeth A Chalmers NEQAS, Birmingham 2006

Management of non response or relapse following HCV therapy. Greg Dore Darrell Crawford

Definition, Prevalence, Pathophysiology and Complications of CKD. JM Krzesinski CHU Liège-ULg Core curriculum Nephrology September 28 th 2013

Breast Pathway Group FEC(100)-Docetaxel: Fluorouracil / Epirubicin / Cyclophosphamide followed by Docetaxel in Early Breast Cancer

Care Pathway for the Administration of Intravenous Iron Sucrose (Venofer )

RELAPSE MANAGEMENT. Pauline Shaw MS Nurse Specialist 25 th June 2010

Regimen : Fludarabine Cyclophosphamide Rituximab (FCR-oral)

CHF INCLEN ADVAC Vaccination in Special Situations: Break-out sessions. Group B

SUMMARY OF PRODUCT CHARACTERISTICS

Enoxaparin for long term anticoagulation in patients unsuitable for oral anticoagulants

Lung Pathway Group Nintedanib (Vargatef) in advanced Non-Small Cell Lung Cancer (NSCLC)

!!! BOLUS DOSE IV. Use 5-10 mcg IV boluses STD ADRENALINE INFUSION. Use IM adrenaline in advance of IV dosing!

Understanding diabetes Do the recent trials help?

Version 2 This guideline describes how to manage patients who are showing signs and symptoms of alcohol withdrawal and Wernicke s Encephalopathy.

Calculating the stage of Renal Disease

NICE guideline Published: 9 December 2015 nice.org.uk/guidance/ng29

GUIDELINES FOR THE TREATMENT OF DIABETIC NEPHROPATHY*

Selective IgA deficiency (slgad)

NHS FORTH VALLEY Adult Adrenal Insufficiency Management Guidelines

Docetaxel, Carboplatin and Trastuzumab (TCH i.e. Taxotere Carboplatin, Herceptin ) for Early Breast Cancer

Open the Flood Gates Urinary Obstruction and Kidney Stones. Dr. Jeffrey Rosenberg Dr. Emilio Lastarria Dr. Richard Kasulke

Management of Children with newly diagnosed type 1 diabetes (up until their 18th Birthday)

Multiple Myeloma Workshop- Tandem 2014

Paediatric fluids 13/06/05

UTI in children. Quick reference guide. Issue date: August Urinary tract infection in children: diagnosis, treatment and long-term management

Paediatric Advanced Warning Score (PAWS)

TACROLIMUS LEVELS IN LIVER TRANSPLANT; INDIAN STUDY

Treatment of Myeloma Bone Disease

Protocol for the safe administration of iodinated contrast media in diagnostic radiology

Rheumatoid Arthritis. GP workshop 15 January 2011

CVP Chemotherapy Regimen for Lymphoma Information for Patients

Frequently Asked Questions

Chronic Kidney Disease and the Electronic Health Record. Duaine Murphree, MD Sarah M. Thelen, MD

MANAGEMENT OF TUBERCULOSIS

Palpitations & AF. Richard Grocott Mason Consultant Cardiologist THH NHS Foundation Trust & Royal Brompton & Harefield NHS Foundation Trust

NHS FORTH VALLEY Multiple Sclerosis Service Management of MS Relapses

Antibiotic-Associated Diarrhea, Clostridium difficile- Associated Diarrhea and Colitis

Rivaroxaban: Prescribing Guidance for the treatment of provoked venous thromboembolism (VTE)

Multiple Myeloma Patient s Booklet

IMPORTANT DRUG WARNING Regarding Mycophenolate-Containing Products

Omega-3 fatty acids improve the diagnosis-related clinical outcome. Critical Care Medicine April 2006;34(4):972-9

Transcription:

Guideline for the Management of Nephrotic Syndrome Renal Unit Royal Hospital for Sick Children Yorkhill Division Please note: the following guideline has not been assessed according to the AGREE (Appraisal of Guidelines for Research and Evaluation) criteria. This will take place at the next guideline review. Nephrotic Syndrome Version: 1.1 Page 1 of 8

Contents Page(s) 1. Introduction 2 2. Definition of Nephrotic Syndrome 2-3 3. Initial Investigation 3 4. Referral to Paediatric Nephrology 3 5. Complications 4 5.1 Hypovolaemia 4 5.2 Infection 4 5.3 Thrombosis 4 6. Treatment of Initial Presentation of Nephrotic 4 Syndrome 6.1 Prednisolone 4-5 6.2 Albumin 5 6.3 Penicillin Prophylaxis 5 6.4 Salt/Fluid Restriction 5 6.5 Vaccination 5 7. Relapse of Nephrotic Syndrome 6 8. Treatment of Relapse of Nephrotic Syndrome 6 8.1 Prednisolone 6 8.2 Albumin 6 8.3 Salt Restriction 6 8.4 Penicillin 6 8.5 Vaccination 6 9. Treatment of Frequent Relapses 6-7 9.1 Low Dose Alternate Day Prednisolone 7 9.2 Levamisole 7 9.3 Cyclophosphamide 7 9.4 Cyclosporin 7 9.5 Mycophenylate Mofitil (MMF) 7 10. Follow Up 8 11. Future Guideline Review 8 1. Introduction This guideline represents our current practice within the Renal Unit and are intended for use by clinicians. These guidelines are based on previous recommendations reviewed in the light of recent literature and will be update regularly. They cover many aspects of the management of typical nephrotic syndrome, but they are not exhaustive, and many not be relevant for children with atypical nephrotic syndrome. There is always a paediatric nephrology consultant on call for the unit who will be happy to discuss difficult or unusual cases. 2. Definition of Nephrotic Syndrome Nephrotic range proteinuria (> 1g/m 2 /day) Hypoalbuminaemia (<25 g/l) Oedema Nephrotic Syndrome Version: 1.1 Page 2 of 8

Classification Idiopathic (primary) nephrotic syndrome o Minimal change (80-90%) o Focal segmental glomerulosclerosis (FSGS) (10-20%) Secondary nephrotic syndrome (HSP, SLE, MPGN) Congenital nephrotic syndrome This document relates only to the management of idiopathic nephrotic syndrome. Children who present with the typical features of nephrotic syndrome (see below) are generally responsive to steroid treatment and a renal biopsy, were it performed, would be likely to show minimal change nephrotic syndrome. Those with atypical features are more likely to be unresponsive to steroid treatment, and a biopsy more likely to show FSGS or one of the other forms of nephrotic syndrome. Therefore children with typical features are started on steroids without recourse to renal biopsy. Those with atypical features should therefore undergo renal biopsy before receiving steroid treatment. Nephrotic Syndrome Typical Features Atypical Features Age 1-10 years <1yr, >10years Normotensive Hypertensive Normal Adrenal Function Elevated Creatinine +/- microscopic haematuria Macroscopic Haematuria 3. Initial Investigation The following investigations should be performed in all children: Blood: FBC, U+E s; Creatinine; LFT s; ASOT; C3/C4; Varicella titres Urine: Urine culture andurinary protein/creatinine ratio BP Urinalysis including glucose A urinary sodium concentration can be helpful in those at risk of hypovolaemia. Varicella status should be known in all children commencing steroids. Hepatitis B status may be appropriate in children at high risk. 4. Referral to Paediatric Nephrology Age < 1 yr Age > 10-12 yrs Persistent hypertension Macroscopic haematuria Low C3/C4 Failure to respond to steroids within 4 weeks Nephrotic Syndrome Version: 1.1 Page 3 of 8

5. Complications The main complications of nephrotic syndrome are hypovolaemia, infection and thrombosis. 5.1 Hypovolaemia The initial examination of children with nephrotic syndrome needs to include an assessment of their intravascular volume. Whilst these children may be very oedematous, they may also be intravascularly depleted. Signs of intravascular depletion are cool peripheries (capillary refill time > 2 secs), a core-peripheral temperature gap of > 2 o C, and tachycardia. Hypotension is a late sign of hypovolaemia, but paradoxical hypertension may be present. A urinary sodium of < 10 mmol/l is a useful investigation to confirm hypovolaemia. 5.2 Infection Loss of complement components and possibly immunoglobulins results in an increased risk of infection. Consider antibiotic prophylaxis whilst patients have significant proteinuria. 5.3 Thrombosis Loss of proteins such as anti-thrombin III contributes to a pro-coagulant state. This might be exacerbaterd by hypovolaemia. 6. Treatment of Initial Presentation of Nephrotic Syndrome 6.1 Prednisolone When the diagnosis of nephrotic syndrome has been made, prednisolone treatment can be started in children with typical features. Children with atypical features should be referred to paediatric nephrology for consideration of renal biopsy. There is increasing evidence that longer initial courses of prednisolone are associated with a lower incidence of relapse, and therefore a 12-week initial course is recommended. The dose of prednisolone is based on surface area. 60 mg/m 2 /day for 4 weeks (maximim 80 mg) 40 mg/m 2 /on alternate days for 4 weeks (maximum 60mg) Reduce dose by 5-10mg/m 2 each week for another 4 weeks then stop Prednisolone can be given as a single dose in the morning with food, or as divided doses during the day. Patients should be issued with a steroid warning card, and they should be aware of the side effects and risks of steroid treatment. Varicella status should be documented clearly in the casenotes and on HISS. If Nephrotic Syndrome Version: 1.1 Page 4 of 8

prednisolone causes gastric irritation, start ranitidine 2mg/kg bid for the duration of steroid treatment. 6.2 Albumin As discussed above the clinical indications for albumin are Clinical hypovolaemia Symptomatic oedema A low serum albumin alone is not an indication for intravenous albumin. If there is evidence of hypovolaemia, give 1 g/kg 20% albumin (5ml/kg) over 4-6 hours. Give 2mg/kg of iv frusemide mid-infusion. If clinically shocked give 10ml/kg 4.5% albumin. Children should be closely monitored during albumin infusions, and where possible they should be administered during working hours. 6.3 Penicillin Prophylaxis Whilst nephrotic, children are at increased risk of infection, particularly with encapsulated organisms such as pneumococcus. There is no evidence that antibiotic prophylaxis is of benefit, and some centres do not use prophylaxis. Penicillin V can be given while there is proteinuria and discontinued when the child goes into remission. Grossly oedematous children are at risk of cellulitis and may benefit from antibiotic prophylaxis. Dose: Under 5 yrs 5yrs or above 125 mg bid 250 mg bid 6.4 Salt/Fluid Restriction A low salt diet is used to try to prevent further fluid retention and oedema. Fluid restriction may also be helpful. These restrictions are lifted once the child goes into remission. 6.5 Vaccination Pneumococcal vaccination is recommended for children with NS. Consider giving at the time of diagnosis. Varicella vaccination is only available on a named patient basis. Response To Treatment Most children with nephrotic syndrome will respond to steroid treatment within 2-4 weeks. A remission is defined as 3 or more days of trace or negative on dipstick testing. Treatment is continued for a total of 12 weeks as outlined above. If proteinuria persists beyond the first 4 weeks of steroid treatment, then children should be referred for renal biopsy. Nephrotic Syndrome Version: 1.1 Page 5 of 8

7. Relapsing Nephrotic Syndrome Up to 60-70 % of children with nephrotic syndrome may have one or more relapse. These are diagnosed if there is +++ or ++++ proteinuria for 3 or more days. Urine should be checked initially twice weekly, then weekly after the first episode, and the families instructed to get in contact should a relapse of proteinuria occur, or if there is ++ for more than 1 week. 8. Treatment of Relapse Nephrotic Syndrome 8.1 Prednisolone Prednisolone treatment should be restarted once a relapse has been diagnosed. 2mg/kg daily (maximum 80 mg) until the urine is negative or trace for 3 days 40 mg/m 2 (maximum 60 mg) on alternate days for 4 weeks then stop or taper the dose over 4-8 weeks 8.2 Albumin The indications for albumin infusion are as for the initial presentation. It is less likely to be needed during a relapse. 8.3 Salt Restriction Whilst there is proteinuria (>++) a no added salt diet is advised. 8.4 Penicillin Whilst there is proteinuria (>++) penicillin can be given. 8.5 Vaccination Consider giving varicella vaccine between relapses in children who are varicella seronegative. Referral to/discussion with Paediatric Nephrology Frequent relapsers Steroid dependency Steroid toxicity 9. Diagnosis and Treatment of Frequent Relapses Frequent relapsers are diagnosed if there is: 2 or more relapses within the first 6 months of presentation 4 or more relapses within any 12 month period This becomes steroid dependency if the relapses are occurring during steroid tapering. Varicella status should be repeated 6 monthly in those who are nonimmune. Nephrotic Syndrome Version: 1.1 Page 6 of 8

If children have frequent relapses, strategies should be adopted to try to reduce the amount of steroid required. 9.1 Low Dose Alternate Day Prednisolone Low dose alternate day steroid treatment (< 10-15 mg/alt days) may prevent relapses, and result in less steroid being given overall. 9.2 Levamisole Levamisole may be beneficial for children who have occasional relapses. It is less useful for children who are steroid dependent. The dose is 2.5 mg/kg/ on alt days for 6 months to a year in the first instance. Reversible neutropenia is a rare but recognised side-effect. A FBC should be checked monthly for the first 3 months. This drug is not licensed in the UK, and has to be imported. 9.3 Cyclophosphamide For children with frequent relapses or those who are steroid dependent consider a course of Cyclophosphamide 3 mg/kg/day for 8 weeks or equivalent. It is best to avoid cutting the tablets. FBC should be monitored for the first few weeks of treatment. 9.4 Cyclosporin Cyclosporin at a dose of 2.5 mg/kg bid usually for 1 year may be useful as a steroid sparing agent. Levels should be checked after 1-2 weeks; aim for a 12 hour trough of 70 120 nmol/l (85-145 ug/l). For children under 5 yrs of age, tid dosing may be necessary. Monitor BP and renal function. 9.5 Mycophenylate Mofitil (MMF) There is some experience of using MMF in children with difficult to treat NS. It may be useful for those children showing signs of cyclosporin toxicity. Doses of 600mg /m 2 /bid have been used. FBC should be monitored for leucopenia. The use of MMF is associated with gastro-intestinal intolerance, mainly diarrhoea. This is an unlicensed indication for MMF. Nephrotic Syndrome Version: 1.1 Page 7 of 8

10. Follow Up GENERAL CONSIDERATIONS DURING FOLLOW UP For children on long-term steroids:- 1) Monitor BP 2) Monitor growth (including bone age and pubertal stage where appropriate) 3) Monitor weight dietetic review where appropriate 4) Glycosuria / HbA1c 5) Bone mineral density / calcium supplements 6) Ophthmology review 7) VACCINATION Pneumococcal: recommended for all children with NS. Varicella: consider in varicella negative children with frequent relapses. Aim to administer vaccine when prednisolone dose is low. 11. Future Guideline Development Should any aspect of this guideline change before the planned review (i.e. new technology or procedural change) then this guideline should be updated accordingly. Future review of this guideline should make use of the AGREE document to ensure that up-to-date evidence and best clinical practice has been used to inform this guideline. For further information regarding guideline development, please contact the Chairperson of the Multi-Professional Clinical Practice Committee. Nephrotic Syndrome Version: 1.1 Page 8 of 8